Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Ace J. Hatch"'
Autor:
John H. Strickler, Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, Michael A. Morse, David Z. Chang, James L. Wells, Kimberly L. Blackwell, P. Kelly Marcom, Christy Arrowood, Emily Bolch, Sherri Haley, Fatima A. Rangwala, Ace J. Hatch, Andrew B. Nixon, Herbert I. Hurwitz
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended ph
Externí odkaz:
https://doaj.org/article/cee4dcf4fc8d4276878e7ac77b99ef23
Autor:
Michael N. Corradetti, MD, PhD, Jordan A. Torok, MD, Ace J. Hatch, PhD, Eric P. Xanthopoulos, MD, JD, Kyle Lafata, PhD, Corbin Jacobs, MD, Christel Rushing, MA, John Calaway, PhD, Greg Jones, MS, Chris R. Kelsey, MD, Andrew B. Nixon, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 4, Iss 4, Pp 748-752 (2019)
Purpose: Concurrent chemoradiation therapy (CRT) is the principal treatment modality for locally advanced lung cancer. Cell death due to CRT leads to the release of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) into the bloodstream, but the
Externí odkaz:
https://doaj.org/article/7539e54ad3a247dcb9328f310f8b3f83
Autor:
Andrew B. Nixon, Federico Innocenti, Hanna K. Sanoff, Michael S. Lee, Dominic T. Moore, Anastasia Ivanova, Kouros Owzar, Chiara Cremolini, Alfredo Falcone, Richard M. Goldberg, Daniele Rossini, Federica Marmorino, Kelli Hammond, John C. Brady, Mark D. Starr, Ace J. Hatch, Alexander B. Sibley, Kirsten Bell Burdett, Jing Lyu, Yingmiao Liu
Regorafenib is a tyrosine kinase inhibitor approved by the FDA for the treatment of patients with chemotherapy refractory metastatic colorectal cancer (mCRC). Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc13a6f6766962d7be65cf3e676a3ff
https://doi.org/10.1158/1535-7163.c.6542764
https://doi.org/10.1158/1535-7163.c.6542764
Autor:
Andrew B. Nixon, Federico Innocenti, Hanna K. Sanoff, Michael S. Lee, Dominic T. Moore, Anastasia Ivanova, Kouros Owzar, Chiara Cremolini, Alfredo Falcone, Richard M. Goldberg, Daniele Rossini, Federica Marmorino, Kelli Hammond, John C. Brady, Mark D. Starr, Ace J. Hatch, Alexander B. Sibley, Kirsten Bell Burdett, Jing Lyu, Yingmiao Liu
Figure S1, consort diagram. Table S1, pts characteristics. Table S2, baseline levels. Table S3, prognostic markers. Table S4, adjusted prognostic markers. Table S5, early changes. Table S6, late changes at disease progression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e03a78e049b3b467e3d8a40989bca42
https://doi.org/10.1158/1535-7163.22520767
https://doi.org/10.1158/1535-7163.22520767
Autor:
Andrew B. Nixon, Herbert I. Hurwitz, Kouros Owzar, Alan P. Venook, Donna Niedzwiecki, Alexander B. Sibley, Ivo Shterev, Ace J. Hatch, Chen Jiang, Stephanie M. Cushman
Supplementary Tables 1-2, Figures 1-4. Supplementary Table 1: List of assay primer sets used in this study. Supplementary Table 2. Table of co-regulation among the 14 genes using a Kendall tau analysis. Supplementary Figure 1: Forest plots showing as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd0dc9d60f4b8f0b0d66c076f8330ebb
https://doi.org/10.1158/1078-0432.22461860
https://doi.org/10.1158/1078-0432.22461860
Autor:
Herbert I. Hurwitz, Kouros Owzar, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Federico Innocenti, Bert H. O'Neil, Heinz-Josef Lenz, Luis Baez-Diaz, Alan P. Venook, Donna Niedzwiecki, John C. Brady, Mark D. Starr, Flora Mulkey, Chen Jiang, Ace J. Hatch, Yingmiao Liu, Alexander B. Sibley, Andrew B. Nixon
Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48adb960f441cc51d88179e4293b09fb
https://doi.org/10.1158/1078-0432.22483455
https://doi.org/10.1158/1078-0432.22483455
Autor:
Andrew B. Nixon, Herbert I. Hurwitz, Kouros Owzar, Alan P. Venook, Donna Niedzwiecki, Alexander B. Sibley, Ivo Shterev, Ace J. Hatch, Chen Jiang, Stephanie M. Cushman
Purpose: Formalin-fixed, paraffin-embedded tumor samples from CALGB 80203 were analyzed for expression of EGFR axis–related genes to identify prognostic or predictive biomarkers for cetuximab treatment.Patients and Methods: Patients (238 total) wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d372fcf3a833af6ceabcad94afcba2
https://doi.org/10.1158/1078-0432.c.6524930.v1
https://doi.org/10.1158/1078-0432.c.6524930.v1
Autor:
Herbert I. Hurwitz, Kouros Owzar, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Federico Innocenti, Bert H. O'Neil, Heinz-Josef Lenz, Luis Baez-Diaz, Alan P. Venook, Donna Niedzwiecki, John C. Brady, Mark D. Starr, Flora Mulkey, Chen Jiang, Ace J. Hatch, Yingmiao Liu, Alexander B. Sibley, Andrew B. Nixon
Purpose:CALGB 80405 compared the combination of first-line chemotherapy with cetuximab or bevacizumab in the treatment of advanced or metastatic colorectal cancer (mCRC). Although similar clinical outcomes were observed in the cetuximab-chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40e7897a5c2ee0cb0491754714576c21
https://doi.org/10.1158/1078-0432.c.6531153
https://doi.org/10.1158/1078-0432.c.6531153
Autor:
Herbert I. Hurwitz, Kouros Owzar, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Federico Innocenti, Bert H. O'Neil, Heinz-Josef Lenz, Luis Baez-Diaz, Alan P. Venook, Donna Niedzwiecki, John C. Brady, Mark D. Starr, Flora Mulkey, Chen Jiang, Ace J. Hatch, Yingmiao Liu, Alexander B. Sibley, Andrew B. Nixon
Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::373d576c170b8429f184ba648f06e0ac
https://doi.org/10.1158/1078-0432.22483458.v1
https://doi.org/10.1158/1078-0432.22483458.v1
Autor:
Andrew B. Nixon, Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, John C. Brady, Donna Niedzwiecki, Alan P. Venook, Luis Baez-Diaz, Heinz-Josef Lenz, Bert H. O'Neil, Federico Innocenti, Jeffrey A. Meyerhardt, Eileen M. O'Reilly, Kouros Owzar, Herbert I. Hurwitz
Publikováno v:
Clinical Cancer Research. 28:2779-2788
Purpose: CALGB 80405 compared the combination of first-line chemotherapy with cetuximab or bevacizumab in the treatment of advanced or metastatic colorectal cancer (mCRC). Although similar clinical outcomes were observed in the cetuximab-chemotherapy